secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prometheus Biosciences, Inc. (—)
CIK:        0001718852
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001193125-23-168524
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck completes acquisition of Prometheus Biosciences for $200/share
--------------------------------------------------------------------

- Merger closed June 16, 2023; Prometheus stockholders received $200 cash per share.
- Prometheus becomes wholly owned subsidiary of Merck; trading suspended, delisting from Nasdaq initiated.
- All prior directors and executive officers replaced by Merck designees; charter and bylaws amended.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/0001193125-23-168524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1718852/000119312523168524/d466468d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-168524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer